BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190515
DTEND;VALUE=DATE:20190517
DTSTAMP:20260514T223809
CREATED:20190114T083448Z
LAST-MODIFIED:20190123T091623Z
UID:19074-1557878400-1558051199@www.pharmajournalist.com
SUMMARY:SMi Presents the 2nd Annual Conference: Injectable Drug Delivery 2019
DESCRIPTION:The SMi Group is pleased to announce the second annual Injectable Drug Delivery conference which will be held in London on the 15th and 16th May 2019. \nThe global injectable drug delivery market is expected to grow from $400 billion to $1200 billion by 2046 with a CAGR of 12.8%. \n \nInjectable drug delivery is a method of drug administration into the body with a needle via various routes including intramuscular and intravenous. These are examples of conventional drug delivery. Recently\, there has been a focus on novel drug delivery\, including needle-free injectors\, and transdermal patches. Long acting injectables (LAI) are developing fast as a push towards patient centric devices drives the industry. Habitually\, injectables were used for delivery of hormones\, vaccines and insulin but as technology advances the application is continuing to expand. Now there is an emphasis on finding solutions to chronic conditions and the biological drugs required involve formulation development challenges for proteins\, including high viscosity and high volume. Self-administrative\, connected\, and ergonomic devices are the new drive. Self-injectable devices include pen injectors for diabetic patients. The wealth of expansion available in the field of connected devices is huge. The regulatory landscape is challenging as it evolves rapidly with the market demand for new devices. \nThe benefits of attending: \nDeveloping on last year’s success\, this event assembles an international audience to include regulatory\, device design\, packaging and formulation professionals.  The devices need to be designed for the new generation of drugs and they need to provide safety with a strong patient focus. This event is will help inspire you to help drive this industry forward and learn about the predicted market trends\, critical digital and chemical developments and the push for patient compliance in a changing regulatory landscape. \nThis conference offers a chance to learn about innovative injectable drug delivery systems with industrial insights on the following: \n– Life cycle management for developing devices that are both user friendly and revenue effective\n– Device design considerations\n– Long acting injectables and bringing these therapeutics to market with case studies\n– Connected devices\, GDPR and cyber security programs\n– Developments in primary packaging\n– Growth in transdermal delivery and subcutaneous infusion devices\n– Digital health partnerships\n– Large volume patch pump innovation examples \nWho should attend \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers\, Scientists\, Researchers of: \n\nAutoinjectors\nWearables\nDevice Engineering\nHuman Factors\nCMC\nInjectables\nSterile Manufacturing\nPackaging\nRegulatory Affairs\n\nFeatured Speakers: \n\nBjorg K. Hunter\, Device Engineering Manager\, GSK\nMiranda Newbery\, Human Factors Consultant\, Inspired Usability\nBlake Green\, Regulatory Affairs Senior Manager\, Devices\, Amgen\nQuentin Le Masne\, Head of Engineering team – Electro-Medical / Drug Delivery Devices\, Merck\nVasco Filipe\, Formulation and Drug Process Development Section Head for Biologics\, Sanofi\nStephen Paboojian\, Senior Project Leader I for Device Development\, Novartis\nTom Lawrie-Fussey\, Digital Services Specialist\, Cambridge Design Partnership\nTerry Reed\, Director of Business development\, AstraZeneca\nJoel Richard\, Head of Technical and Pharmaceutical Operations\, MedinCell\n\n*Plus\, pre-conference workshops – 14th May 2019 \nEARLY-BIRD RATES: \n\nBOOK BY 31st JANUARY AND SAVE £400\nBOOK BY 28th FEBRUARY AND SAVE £200\nBOOK BY 29th MARCH AND SAVE £100\n\nLinkedIn: @SMi Pharma \nTwitter: @SMiPharm #SMi \nTo learn more about this event\, and to register online\, visit www.injectable-drug-delivery.com/pharmajwl
URL:https://www.pharmajournalist.com/event/injectable-drug-delivery-2019/
LOCATION:Copthorne Tara Hotel London Kensington\, Copthorne Tara Hotel London Kensington\, London\, SW7 4DN\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
END:VCALENDAR